Cytek Biosciences, Inc. (CTKB)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$5.88-1.34%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · CTKB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -21.7% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 6.7% |
Growth built into the price is above our model estimate.
The price assumes 28.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 29 industry peers · Company calendar date is not available
CTKB — litigation filed
Dated 2026-08-24
Other Events. On August 21, 2026, the Company announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in the Company’s favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents…
Why it matters: Cytek reported a $12.2M net loss in Q2 as operating costs rose. A smaller loss would show progress toward steadier results.
Watch forQ3 net loss is smaller than $12.2M and adjusted EBITDA is above the Q2 loss of $1.5M.
Also watch forQ3 net loss exceeds $12.2M or adjusted EBITDA loss is larger than $1.5M.
Why it matters: The August jury found infringement on one claim under the doctrine of equivalents. The court's next ruling may clarify the case's impact.
Watch forA court filing or company update says the one-claim verdict was reversed or dismissed. It says the case ended without a payment or sales limit.
Also watch forA court order upholds the finding and sets a payment or limits sales of an affected product.
Why it matters: Service and reagent sales made up 35% of trailing-year revenue in Q2. More repeat sales can support steadier growth.
Supportive ifTrailing-12-month recurring revenue stays at or above 35% of total revenue in the next report.
Worry ifTrailing-12-month recurring revenue falls below 35% of total revenue.
Why it matters: New placements grow the installed base and can bring more service and reagent sales. Cytek had 3,933 instruments installed at Q2 end.
Supportive ifCytek reports at least 142 new instrument placements in Q3, keeping pace with Q2.
Worry ifCytek reports fewer than 125 new placements in Q3, below the Q1 count.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$152 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $548 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,294 loss on $10,000 · 42.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.